NervGen Pharma Corp. Common stock
NASDAQ: NGEN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adam H. Rogers
- Employees
- 7
- Headquarters
- West Vancouver, Canada
- IPO year
- 2021
- Market cap
- $163.6M
- Website
- https://www.nervgen.com
Loading NGEN…
Loading profile data…Frequently asked questions about NGEN
What does NervGen Pharma Corp. Common stock (NGEN) do?
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair i...
Where does NGEN trade?
NervGen Pharma Corp. Common stock (NGEN) trades on the NASDAQ Capital Market.
What sector is NGEN in?
NervGen Pharma Corp. Common stock (NGEN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NervGen Pharma Corp. Common stock?
Adam H. Rogers is the chief executive officer of NervGen Pharma Corp. Common stock (NGEN).
Where is NervGen Pharma Corp. Common stock headquartered?
NervGen Pharma Corp. Common stock is headquartered in Canada.
Does NGEN pay a dividend?
NervGen Pharma Corp. Common stock (NGEN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NGEN go public?
NervGen Pharma Corp. Common stock (NGEN) completed its initial public offering in 2021.